Regulatory · source year

2021 regulatory records

49 selected, source-linked regulatory records dated 2021. This is selective source coverage, not a complete timeline.

Dated records

49 selected records.

Peptide profiles

26 connected profiles.

Cited sources

49 distinct public records.

Cited chronology

Dated source records

All record types in 2021 →

December 2021

6 records

November 2021

6 records

Daptomycin + 1 more

Federal Register notice 2021-25111

The Federal Register published notice 2021-25111, attributed to FDA and its parent HHS department, on 2021-11-18. Its official title is “Discovery Therapeutics, LLC, et al.; Withdrawal of Approval of 18 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin and Eptifibatide.

Source: Federal Register via GovInfo ↗

→

Glucagon + 1 more

Federal Register notice 2021-24431

The Federal Register published notice 2021-24431, attributed to FDA and its parent HHS department, on 2021-11-09. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon and Leuprolide.

Source: Federal Register via GovInfo ↗

→

Afamelanotide

Federal Register notice 2021-24074

The Federal Register published notice 2021-24074, attributed to FDA and its parent HHS department, on 2021-11-04. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; SCENESSE,” and PeptideScanner's exact reviewed identity mapping connects the document to Afamelanotide.

Source: Federal Register via GovInfo ↗

→

October 2021

3 records

September 2021

5 records

Exenatide

Federal Register notice 2021-18928

The Federal Register published notice 2021-18928, attributed to FDA and its parent HHS department, on 2021-09-02. Its official title is “Proposal To Refuse To Approve a New Drug Application for ITCA 650 (Exenatide in DUROS Device); Opportunity for a Hearing,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.

Source: Federal Register via GovInfo ↗

→

August 2021

5 records

Leuprolide + 1 more

Federal Register notice 2021-18072

The Federal Register published notice 2021-18072, attributed to FDA and its parent HHS department, on 2021-08-23. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Semaglutide.

Source: Federal Register via GovInfo ↗

→

July 2021

1 record

Eptifibatide

Federal Register notice 2021-16047

The Federal Register published notice 2021-16047, attributed to FDA and its parent HHS department, on 2021-07-28. Its official title is “Fresenius Kabi USA, LLC, et al.; Withdrawal of Approval of 15 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Eptifibatide.

Source: Federal Register via GovInfo ↗

→

June 2021

7 records

Octreotide

Federal Register notice 2021-11575

The Federal Register published notice 2021-11575, attributed to FDA and its parent HHS department, on 2021-06-02. Its official title is “Determination That SANDOSTATIN (Octreotide Acetate) Injection, Equal to 0.2 Milligrams Base/Milliliter and Equal to 1 Milligrams Base/Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide.

Source: Federal Register via GovInfo ↗

→

May 2021

5 records

April 2021

5 records

March 2021

2 records

Bremelanotide + 1 more

Federal Register notice 2021-06202

The Federal Register published notice 2021-06202, attributed to FDA and its parent HHS department, on 2021-03-25. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Bremelanotide and Octreotide.

Source: Federal Register via GovInfo ↗

→

February 2021

2 records

January 2021

2 records

Nesiritide

Federal Register notice 2021-00118

The Federal Register published notice 2021-00118, attributed to FDA and its parent HHS department, on 2021-01-08. Its official title is “Determination That ARALEN (Chloroquine Phosphate) Oral Tablets, 500 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Nesiritide.

Source: Federal Register via GovInfo ↗

→